37
Participants
Start Date
August 31, 2011
Primary Completion Date
September 30, 2018
Study Completion Date
September 30, 2018
An FDA approved continuous renal replacement device
"70ml/kg/hr for treatment group for 48 hours with the following requirements:~* double lumen dialysis catheter should be placed in the internal jugular or femoral vein~* Anticoagulation will be determined by prescribing physician~* Use of 1.4 m2 or larger biocompatible synthetic hollow-fiber dialysis membrane that is changed every 24 hours~* Blood flow rate will be set to ensure a filtration fraction of no more than 25%~* Monitoring for electrolytes (specifically K+, Mg, Ca, and phos) during HVHF must be performed at least every 6 hours~* Replacement fluids will be bicarbonate-buffered with appropriate adjustments when citrate-anticoagulation is utilized~* All antibiotics will be dose adjusted for renal replacement therapy"
Control Group
Both groups will receive 'contemporary' care via consideration of the Burn-specific Sepsis Bundle adapted from the most recent Surviving Sepsis Campaign (SSC) (1) recommendations and specifically modified to our patient population
The Burn Center at Washington Hospital Center, Washington D.C.
Doctors Hospital-Joseph M Still Burn Center, Augusta
Tampa General Hospital, Tampa
Regional Medical Center at Memphis, Memphis
Loyola University Medical Center, Maywood
University of Kansas Hospital, Kansas City
University of Texas Southwestern Medical Center-Burn Center Parkland Health, Dallas
US Army Institute of Surgical Research, Fort Sam Houston
Arizona Burn Center, Phoenix
Collaborators (1)
United States Army Institute of Surgical Research
FED
Tampa General Hospital
OTHER
Medstar Health Research Institute
OTHER
Loyola University
OTHER
University of Texas Southwestern Medical Center
OTHER
Valleywise Health
OTHER
University of Tennessee
OTHER
University of Kansas Medical Center
OTHER
Doctors Hospital-Joseph M Still Burn Center
UNKNOWN
American Burn Association
OTHER